Pharsight

Steglatro generic

Steglatro is an anti-diabetic drug owned by Merck Sharp Dohme. The active ingredient in Steglatro is ertugliflozin. The drug was first authorized for market use on December 19, 2017. Steglatro holds a total of 1 patent.

When will Steglatro generic be available?

Available in an oral dosage form, the Steglatro generic is tentatively set to be released after July 13, 2030, following the expiration of the last patent. This patent, US8080580, is titled 'Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives' and it expires July 13, 2030.

Steglatro uses

Steglatro, containing the active ingredient ertugliflozin, can be used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. Its effectiveness is largely attributed to ertugliflozin's ability.

Steglatro patent expiration

Steglatro holds one patent, which is not due to expire until July 13, 2030. The patent is US8080580, titled 'Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives'. Upon its expiration, generic versions of the drug may become available. Steglatro generic will be possible to release upon this expiration. Below are the details of the patent:

Steglatro dosage

Want to ask something?